OpenAI buys AI biotech startup Orchestra Bio to strengthen its life-science platform
OpenAI announced the acquisition of Orchestra Bio, a four-year-old AI biotech software firm, adding its team and tools to the company's Rosalind life-science model.
OpenAI confirmed on Tuesday that it has acquired Orchestra Bio, an AI-driven biotech software startup founded four years ago. Orchestra Bio, backed by investors including Andreessen Horowitz, Atria and 8VC with roughly $20 million raised by 2025, builds AI agents that automate routine aspects of drug-discovery operations, from financial tracking to clinical-trial scheduling. OpenAI will absorb the company’s personnel and technology to enhance its Rosalind model for life-science research and the related Rosalind Workbench platform, which helps scientists design experiments and interpret results.
The move follows reports that Rosalind already serves major pharma players such as Moderna and Novo Nordisk. Analysts view the purchase as part of a broader trend where top AI labs, including Anthropic, are developing software solutions for large sectors like pharma, raising concerns about future competition. In this case, Orchestra Bio is being integrated rather than eliminated.
Why it matters
The acquisition expands OpenAI's reach into biotech, potentially accelerating AI-driven drug discovery and reshaping pharma R&D.
In this story
